Department of Medical Oncology, Hospital Universitario La Paz, 28046, Madrid, Spain.
, Paseo de la Castellana 261, 28045, Madrid, Spain.
Clin Transl Oncol. 2022 May;24(5):796-808. doi: 10.1007/s12094-021-02745-z. Epub 2022 Jan 11.
Transarterial radioembolization (TARE) with yttrium-90 (Y90) is a promising alternative strategy to treat liver tumors and liver metastasis from colorectal cancer (CRC), as it selectively delivers radioactive isotopes to the tumor via the hepatic artery, sparring surrounding liver tissue. The landscape of TARE indications is constantly evolving. This strategy is considered for patients with hepatocellular carcinoma (HCC) with liver-confined disease and preserved liver function in whom neither TACE nor systemic therapy is possible. In patients with liver metastases from CRC, TARE is advised when other chemotherapeutic options have failed. Recent phase III trials have not succeeded to prove benefit in overall survival; however, it has helped to better understand the patients that may benefit from TARE based on subgroup analysis. New strategies and treatment combinations are being investigated in ongoing clinical trials. The aim of this review is to summarize the clinical applications of TARE in patients with gastrointestinal malignancies.
经动脉放射性栓塞术（TARE）联合钇-90（Y90）是治疗肝脏肿瘤和结直肠癌（CRC）肝转移的一种很有前途的替代策略，因为它通过肝动脉将放射性同位素选择性地输送到肿瘤，从而使周围的肝组织免受影响。TARE 的适应证范围不断扩大。这种策略适用于那些患有局限于肝脏且肝功能正常的肝细胞癌（HCC）患者，他们不能进行 TACE 或全身治疗。对于结直肠癌肝转移患者，如果其他化疗方案失败，建议采用 TARE。最近的 III 期临床试验未能证明总生存期的获益，但有助于根据亚组分析更好地了解可能从 TARE 中获益的患者。目前正在进行的临床试验正在研究新的策略和治疗组合。本文旨在总结 TARE 在胃肠道恶性肿瘤患者中的临床应用。
